How Solving a Problem with Genetic Medicines May Solve Another with Infectious Diseases

Episode Summary

Executive Summary: John Lewis of Aegis Life explains how DNA-encoded antibodies and vaccines could make infectious-disease countermeasures cheaper, more scalable, and fridge-stable for use in low-resource settings. The discussion centers on Aegis’ Fusogenix PLV delivery platform, Gates Foundation funding, and the promise of rapid-response genetic medicines for malaria, HIV, and future outbreaks.

Main Topics: Global infectious-disease burden and inequity (Priority: 5/5): Lewis argues that communicable diseases disproportionately affect low- and middle-income countries, where mortality, life-years lost, and access to care are far worse than in wealthier regions. Infrastructure and cold-chain barriers (Priority: 5/5): The conversation highlights how refrigeration, transport, and storage requirements limit deployment of advanced vaccines and biologics, especially in rural and resource-constrained settings. DNA-encoded antibodies as a therapeutic strategy (Priority: 5/5): Aegis aims to encode neutralizing antibodies in DNA so the body produces the therapy itself, reducing manufacturing, storage, and administration complexity versus infused antibodies. Fusogenix PLV delivery platform (Priority: 4/5): Lewis describes Entos/Aegis’ proteolipid vehicle as a second-generation lipid-like delivery system that can deliver DNA or RNA via fusion, enabling fridge-stable genetic medicines. Gates Foundation investment and malaria/HIV focus (Priority: 4/5): A $4.5 million investment from the Gates Foundation supports development of DNA-encoded antibody therapies targeting malaria, HIV, and related infectious diseases. Rapid development and scalable manufacturing (Priority: 4/5): The platform is positioned as a fast-response technology that can move from pathogen sequencing to clinical candidate development in weeks and potentially scale at very low cost. Development status and prioritization (Priority: 3/5): Aegis’ COVID-19 DNA vaccine reached phase 1 in Canada and phase 2 in Burkina Faso; the company is prioritizing unmet needs with validated targets where platform biology is well matched.

Key Arguments: Infectious diseases remain a much larger burden in low- and middle-income countries, making scalable, affordable interventions a global health priority. Cold-chain constraints prevent effective therapies from reaching many patients; fridge-stable products could materially improve access. Encoding neutralizing antibodies in DNA could let patients’ own cells manufacture protective or therapeutic proteins, cutting cost and simplifying deployment. Fusogenix PLV is designed to deliver DNA more effectively than conventional methods, addressing a core barrier to DNA medicines. The Gates Foundation’s support is intended not only to fund development but also to validate the platform and attract additional capital. Agenis/Aegis believes genetic medicine can accelerate outbreak response by enabling rapid design, manufacture, and scale-up after pathogen identification. Vaccines are powerful but not universal; DNA-encoded antibody therapies may help immunocompromised and older patients who respond poorly to vaccination. The technology is being pursued where unmet need is highest and where low-cost deployment could have the greatest public-health impact.

Data Points: Communicable disease burden: About 10 times higher - Lewis says communicable-disease mortality and years of life lost are roughly 10x higher in low- and middle-income countries. Annual deaths from malaria, HIV, and tuberculosis: Over 2.8 million - Used to illustrate the scale of infectious-disease mortality worldwide. Gates Foundation investment: $4.5 million - Funding provided to Aegis to advance malaria, HIV, and other infectious-disease programs. Lives saved by immunization: 154 million lives - WHO estimate cited for global immunization efforts over the past 50 years. Lives saved per minute: Six lives every minute - Lewis quotes the WHO finding to emphasize immunization impact. People living with HIV globally (end of 2022): About 39 million - Global HIV prevalence cited in the discussion of unmet need. People with HIV lacking ART access: 9.2 million - Illustrates treatment gaps for HIV. Global malaria cases in 2022: 249 million - Scale of malaria burden referenced by Lewis. Global malaria deaths in 2022: Over 600,000 - Magnitude of malaria mortality cited. Share of malaria cases in Africa: 94% - African region’s disproportionate malaria burden. Share of malaria deaths in under-fives in Africa: 78% - Highlights pediatric vulnerability. Aegis COVID vaccine phase 1 location: Canada - Initial clinical testing site for the company’s DNA-based COVID-19 vaccine. Aegis COVID vaccine phase 2 location: Burkina Faso - Subsequent phase 2 testing conducted in Africa. Projected cost per dose at scale: Less than $5, potentially under $1 - Lewis says the DNA vaccine could be manufactured very cheaply at scale.

Pivotal Quotes: "the burden of communicable diseases is about 10 times higher in low- and middle-income countries" — John Lewis: Explaining why infectious-disease technologies must be designed for affordability and access. "your body can actually make them internally and circulate them around" — John Lewis: Describing the core mechanism behind DNA-encoded antibodies. "we can either make RNA-based or DNA-based medicines... on the order of weeks" — John Lewis: On the platform’s rapid-response potential for outbreak countermeasures.

Implications: If Aegis succeeds, genetic medicines could become cheaper, fridge-stable, and easier to deploy globally, expanding access beyond wealthy health systems and improving outbreak preparedness for malaria, HIV, and future pandemics.